BioSpace News Archive

PROCEPT ® BioRobotics Corporation , a surgical robotics company developing intelligent solutions to transform the field of urology, announced that Blue Cross Blue Shield of Massachusetts and EmblemHealth are now providing insurance coverage for Aquablation therapy delivered by the AquaBeam® Robotic System for the treatment of benign prostatic hyperplasia (BPH).

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid)

-- Remus Vezan, M.D., Ph.D., joins as CMO to lead clinical development -- -- John Rossi will direct translational research efforts --

Normal Progression of Bone Age with Chronological Age Over 60 Months with Vosoritide for Children with Achondroplasia

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2021 on Thursday, April 29, 2021, following the close of the market.

The winners of the ‘Red Dot Award: Product Design 2021’ have been announced, and Ambu is a double winner with awards for the company’s cystoscope and duodenoscope – both single-use endoscopes.

Piezo Motion Corp, a leader and innovator of precision motor technology, today announced a distribution partnership with Serticom b.v., a dynamic player in the market of industrial electronic components, to provide motion control systems to the Netherlands, Belgium, Luxemburg, Germany, Austria, and Switzerland.

the American Urological Association announced its Board of Directors has approved Matthew Nielsen, MD, MS, FACS, as the next chair of the AUA Science and Quality Council.

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies, today announced the launch of a national sales force expansion.

XOMA Corporation announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. innate cell engager programs for which XOMA could receive future economics.